BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 21099110)

  • 1. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression.
    Sharma A; Yeow WS; Ertel A; Coleman I; Clegg N; Thangavel C; Morrissey C; Zhang X; Comstock CE; Witkiewicz AK; Gomella L; Knudsen ES; Nelson PS; Knudsen KE
    J Clin Invest; 2010 Dec; 120(12):4478-92. PubMed ID: 21099110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RB tumor suppressor: a gatekeeper to hormone independence in prostate cancer?
    Macleod KF
    J Clin Invest; 2010 Dec; 120(12):4179-82. PubMed ID: 21099103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer.
    Davis JN; Wojno KJ; Daignault S; Hofer MD; Kuefer R; Rubin MA; Day ML
    Cancer Res; 2006 Dec; 66(24):11897-906. PubMed ID: 17178887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer.
    Han D; Chen S; Han W; Gao S; Owiredu JN; Li M; Balk SP; He HH; Cai C
    Cancer Res; 2019 Oct; 79(20):5260-5271. PubMed ID: 31444154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer.
    Mandigo AC; Shafi AA; McCann JJ; Yuan W; Laufer TS; Bogdan D; Gallagher L; Dylgjeri E; Semenova G; Vasilevskaya IA; Schiewer MJ; McNair CM; de Bono JS; Knudsen KE
    Cancer Res; 2022 Jan; 82(2):221-234. PubMed ID: 34625422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression.
    Kawamura N; Nimura K; Saga K; Ishibashi A; Kitamura K; Nagano H; Yoshikawa Y; Ishida K; Nonomura N; Arisawa M; Luo J; Kaneda Y
    Cancer Res; 2019 Oct; 79(20):5204-5217. PubMed ID: 31431456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of tumor suppressor dysregulation in prostate cancer progression.
    Dean JL; Knudsen KE
    Curr Drug Targets; 2013 Apr; 14(4):460-71. PubMed ID: 23410128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells.
    Torosyan Y; Simakova O; Naga S; Mezhevaya K; Leighton X; Diaz J; Huang W; Pollard H; Srivastava M
    Int J Cancer; 2009 Dec; 125(11):2528-39. PubMed ID: 19610065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Zoubeidi A; Kuruma H; Fazli L; Lamoureux F; Beraldi E; Monia BP; MacLeod AR; Thüroff JW; Gleave ME
    Mol Cancer Ther; 2011 Feb; 10(2):347-59. PubMed ID: 21216933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [RB, guardian of prostatic tumor progression].
    Bénard J; Massard C
    Bull Cancer; 2011 Feb; 98(2):91-2. PubMed ID: 21591299
    [No Abstract]   [Full Text] [Related]  

  • 12. Induction of androgen receptor-dependent apoptosis in prostate cancer cells by the retinoblastoma protein.
    Wang X; Deng H; Basu I; Zhu L
    Cancer Res; 2004 Feb; 64(4):1377-85. PubMed ID: 14973061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer.
    Bohrer LR; Chen S; Hallstrom TC; Huang H
    Endocrinology; 2010 Nov; 151(11):5136-45. PubMed ID: 20881251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
    Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
    Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
    Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
    Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutamine tract length of human androgen receptors affects hormone-dependent and -independent prostate cancer in mice.
    Albertelli MA; O'Mahony OA; Brogley M; Tosoian J; Steinkamp M; Daignault S; Wojno K; Robins DM
    Hum Mol Genet; 2008 Jan; 17(1):98-110. PubMed ID: 17906287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential impact of RB status on E2F1 reprogramming in human cancer.
    McNair C; Xu K; Mandigo AC; Benelli M; Leiby B; Rodrigues D; Lindberg J; Gronberg H; Crespo M; De Laere B; Dirix L; Visakorpi T; Li F; Feng FY; de Bono J; Demichelis F; Rubin MA; Brown M; Knudsen KE
    J Clin Invest; 2018 Jan; 128(1):341-358. PubMed ID: 29202480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate.
    He Y; Johnson DT; Yang JS; Wu H; You S; Yoon J; Lee DH; Kim WK; Aldahl J; Le V; Hooker E; Yu EJ; Geradts J; Cardiff RD; Sun Z
    Oncogene; 2019 Sep; 38(38):6507-6520. PubMed ID: 31358900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.